Remicade, i kombination med methotrexat, er indiceret til: reduktion af sygdomstegn og symptomer samt forbedring af fysisk funktionsevne hos: • patienter med aktiv sygdom, når responset til sygdomsmodulerende antireumatiske lægemidler (DMARDs), inklusive methotrexat, har været utilstrækkeligt. • patienter med alvorlig, aktiv og progressiv sygdom, der ikke tidligere er behandlet med methotrexat eller andre former for Disease Modifying Anti- Rheumatic Drugs (DMARD).
Remicade, in combination with methotrexate, is indicated for: the reduction of signs and symptoms as well as the improvement in physical function in: • patients with active disease when the response to disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, has been inadequate. • patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.